Solution for the scale-up and production of mRNA-based vaccines and therapeutics
Dillico is developing an infrastructure of digital tools, equipment and services suited to your mRNA-LNP platform, to help you meet the challenges you face.
Our proprietary flow-technology solution allows the same piece of equipment to produce mRNA vaccine and therapeutics at any scale, from discovery to commercial manufacturing, while offering unique real-time and remote monitoring capabilities, thus facilitating operations and technology transfers.
Advantages of our solution
Quality – Fully enclosed, monitored and digitalized process
Direct Scale-up & Flexibility – 1,000 to 10 million+ doses per run
Optimized Costs – COGS reduced by 80%
Manufacturing at a regional level – Automated equipment with a 4 sq/m footprint